Lates News

Eli Lilly and Company fell 2.2% in early trading on Thursday. It was reported earlier that the company had stopped a study on an experimental drug aimed at preventing excessive muscle loss in obese patients, citing strategic business considerations. In addition, Eli Lilly also plans to launch its experimental weight loss drug orforpligron in India.